The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis
| Autor: | Julia Sinclair, David S. Baldwin, Lorenzo Leggio, Hugo J F Amaro, Roberta Agabio |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Agonist
Baclofen medicine.medical_specialty Alcohol Drinking medicine.drug_class Cognitive Neuroscience Alcohol use disorder Anxiety Placebo 03 medical and health sciences Behavioral Neuroscience chemistry.chemical_compound 0302 clinical medicine Rating scale Internal medicine medicine Humans 0501 psychology and cognitive sciences 050102 behavioral science & comparative psychology business.industry 05 social sciences medicine.disease Clinical trial Alcoholism Neuropsychology and Physiological Psychology chemistry GABA-B Receptor Agonists Meta-analysis medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Neuroscience & Biobehavioral Reviews. 125:296-313 |
| ISSN: | 0149-7634 |
| DOI: | 10.1016/j.neubiorev.2020.12.030 |
| Popis: | Given the high coexistence of anxiety symptoms in people with alcohol use disorder (AUD), we aimed to determine the influence of anxiety symptoms on outcomes in patients with AUD treated with the GABAB receptor agonist baclofen. A meta-analysis of 13 comparisons (published 2010-2020) including baseline and outcome data on alcohol consumption and anxiety after 12 weeks was undertaken. There were significantly higher rates of abstinent days in patients treated with baclofen compared to placebo (p = 0.004; high certainty evidence); specifically in those with higher baseline anxiety levels (p < 0.00001; high certainty evidence) compared to those with lower baseline anxiety levels (p = 0.20; moderate certainty evidence). The change in anxiety ratings over 12 weeks did not differ between those treated with baclofen or placebo (p = 0.84; moderate certainty evidence). This may be due to different anxiety constructs being measured by scales not validated in this patient group, or that anxiety is not a biobehavioral mechanism by which baclofen may reduce alcohol drinking. Given the prevalence of anxiety symptoms in AUD all these factors warrant further research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect